Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Experts are expecting strong performance driven by the robust sales of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potential pressures f